Which infections are caused by Gram‑positive bacteria versus Gram‑negative bacteria, and what antibiotics are recommended to treat each type?

Classification of Gram-Positive and Gram-Negative Infections with Antibiotic Recommendations

Gram-positive infections should be treated with penicillins (benzylpenicillin, ampicillin, amoxicillin), cloxacillin for staphylococci, or vancomycin for resistant strains, while Gram-negative infections require aminoglycosides (gentamicin, amikacin) often combined with cephalosporins (cefotaxime, ceftriaxone) or carbapenems for resistant organisms 1.

Gram-Positive Bacteria and Their Infections

Common Gram-Positive Pathogens:

• Staphylococcus aureus (including MRSA)
• Coagulase-negative staphylococci
• Streptococcus pneumoniae
• Group B Streptococcus (GBS)
• Enterococcus species (including VRE)

Antibiotic Selection for Gram-Positive Infections:

First-line agents:

• Penicillin, cloxacillin, and erythromycin cover 90% of Gram-positive infections 2
• Benzylpenicillin, ampicillin, or amoxicillin for streptococcal infections 1
• Cloxacillin for methicillin-sensitive staphylococci 1

For resistant organisms:

• Vancomycin for MRSA and coagulase-negative staphylococci 1, 3
• Linezolid and quinupristin/dalfopristin for vancomycin-resistant strains 3
• Teicoplanin as an alternative glycopeptide 3

Critical resistance patterns: Approximately 60% of ICU staphylococcal infections are now MRSA, and vancomycin-resistant enterococci continue to rise 4. Recent data shows Staphylococcus aureus demonstrates 100% sensitivity to ampicillin, amoxiclav, teicoplanin, and linezolid in some settings, but variable vancomycin sensitivity 5.

Gram-Negative Bacteria and Their Infections

Common Gram-Negative Pathogens:

• Escherichia coli (most common, 36.6% of isolates)
• Klebsiella pneumoniae
• Pseudomonas aeruginosa
• Enterobacter species
• Acinetobacter baumannii
• Stenotrophomonas maltophilia

Antibiotic Selection for Gram-Negative Infections:

First-line combinations:

• Aminoglycosides (gentamicin or amikacin) combined with a beta-lactam 1
• Gentamicin + ampicillin/amoxicillin/benzylpenicillin for empiric coverage 1
• Add cefotaxime or ceftriaxone when Gram-negative sepsis is suspected or confirmed 1

For resistant organisms:

• Carbapenems (imipenem, meropenem) for extended-spectrum beta-lactamase producers 5
• Aztreonam for aerobic Gram-negative bacilli 6
• E. coli shows 100% sensitivity to aztreonam, 98% to nitrofurantoin, and 94-95% to carbapenems 5

Resistance concerns: E. coli demonstrates decreased sensitivity to ampicillin (25%), cefuroxime (34%), and ceftriaxone (39%) 5. Pseudomonas aeruginosa with difficult-to-treat resistance and carbapenem-resistant Enterobacterales require specialized treatment approaches 7.

Practical Treatment Algorithm

For Empiric Sepsis Treatment (when organism unknown):

1. Start broad-spectrum coverage: Ampicillin/amoxicillin/benzylpenicillin + gentamicin 1
2. If Gram-negative suspected: Add cefotaxime or ceftriaxone immediately 1
3. If Gram-positive confirmed: Stop Gram-negative coverage, continue appropriate penicillin or add vancomycin if MRSA suspected
4. If Gram-negative confirmed: Stop benzylpenicillin, continue aminoglycoside + cephalosporin or carbapenem 1

Second-Line Options:

• Amikacin + cloxacillin as alternative combination 1
• Cefotaxime or ceftriaxone (Watch category antibiotics) for resistant cases 1

Critical Pitfalls to Avoid

Do not use vancomycin empirically unless MRSA is strongly suspected—reserve it to prevent further resistance development 3, 4.

Do not rely on ampicillin alone for Gram-negative coverage—it has only 25% sensitivity against E. coli 5.

Always add aminoglycoside coverage when treating serious Gram-negative infections, as monotherapy with beta-lactams increases treatment failure risk 8.

Monitor antibiotic levels in critically ill patients—subinhibitory levels lead to breakthrough bacteremia and treatment failure 8.

The combination approach (beta-lactam + aminoglycoside) remains superior to monotherapy for Gram-negative bacteremia, particularly with Pseudomonas aeruginosa or in neutropenic patients 8. Local antibiograms should guide final antibiotic selection, as resistance patterns vary significantly by institution 1, 5.